The Behçet's disease;Choroba Behçeta

Reumatologia

Volumn 42, Issue 1, 2004, Pages 77-85

  Sułek, Marian ^a   Bachta, Artur ^a   Tłustochowicz, Witold ^a  

^a Klinika Reumatologii   (Poland)

Author keywords

Beh et disease; Diagnostic criteria; Therapy

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA BLOCKING AGENT; UNCLASSIFIED DRUG;

BEHCET DISEASE; GERMANY; MIGRATION; POLAND; REVIEW; SOUTHERN EUROPE; WESTERN EUROPE;

EID: 18544405359     PISSN: 00346233     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Accardo-Palumbo A., Triolo G., Carbone M.G. et al.: Polymorphonuclear leukocyte myeloperoxidase levels in patients with Behçet's disease. Clin. Exp. Rheumatol., 2000, 18, 495.
2. Bang D.: Clinical spectrum of Behçet's disease. J. Dermatol., 2001, 28, 610.
3. Bavraktar Y., Ozaslan E., Thiel D.H.: Gastrointestinal manifestations of Behçet's disease. J. Clin. Gastroenterol., 2002, 30, 144.
4. Benamour S.: Rheumatic manifestations of Behçet's disease. Ann. Med. Interne, 1999, 150, 562.
5. Calguneri M., Ozturk M.A., Ertenli I. et al.: Effects of interferon alfa treatment on the clinical course of refrectory Behçet's disease: an open study. Ann. Rheum. Dis., 2003, 62, 492.
6. Cassoux N., Fardeau C., Lehoang P.: Ocular manifestations of Behçet's disease. Ann. Med. Interne, 1999, 150, 529.
7. Chang H.K., Cheon K.S.: The clinical significance of a pathergy reaction in patients with Behçet's disease. J. Korean. Med. Sci., 2002, 17, 371.
8. Elbrit D., Asher I., Sthoeger Z.M.: Behçet's disease-clinical presentation, diagnostic and therapeutic approach. Harefuah, 2002, 141, 462.
9. Er H., Everklioglu C., Cumurcu T. et al.: Serum homocysteine level is increased and correlated with endothelin-1 and nitric oxide in Behçet's disease. Br. J. Ophtalmol., 2002, 86, 653.
10. Espinosa G., Carvera R., Reverter J.C.: Vascular involvement in Behçet's disease. Isr. Med. Assoc., 2002, 4, 614.
11. Femiano F.: Behçet's disease: recent findings. Review of the literature. Minerva Stomatol., 2000, 49, 187.
12. Frassanito M.A., Dammacco R., Cafforio P. et al.: Th1 polarisation of the immune response in Behçet's disease: a putative pathogenic role of interleukin-12. Arthritis Rheum., 1999, 42, 1967.
13. Fresko I., Soy M., Hamuryudan V. et al.: Genetic anticipation in Behçet's syndrome. Ann. Rheum. Dis., 1998, 57, 45.
14. Fresko I., Yurdakul S., Hamuryudan V. et al.: The management of Behçet's syndrome. Ann. Med. Interne, 1999, 150, 576.
15. Freysdottir J., Lau S., Fortune F. et al.: Gammadelta T cells in Behçet's disease (BD) and recurrent aphtous stomatitis (RAS). Clin. Exp. Immunol., 1999, 118, 451.
16. Grana Gil J., Sanchez Meizoso M.O.: Diagnostic criteria and differential diagnosis of Behçet's disease. Rev. Clin. Esp., 2002, 202, 120.
17. Gul A., Inanc M., Ocal L. et al.: Familial aggregation of Behçet's disease in Turkey. Ann. Rheum. Dis., 2000, 59, 622.
18. International Study Group for Behçet's disease: Criteria for the diagnosis of Behçet's disease. Lancet, 1990, 335, 1078.
19. Kaya T.I., Dur H., Tursen U. et al.: Association of class I HLA antigens with the clinical manifestations of Turkish patients with Behçet's disease. Clin. Exp. Dermatol., 2002, 27, 498.
20. Kobayashi M., Ito M., Nakagawa A. et al.: Neutrophil and endothelial cell activation in the vasa vasorum in vasculo-Behçet disease. Histopathology, 2000, 36, 362.
21. Kone-Paut I., Geisler I., Wechsler B. et al.: Familiar aggregation in Behçet's disease: high frequency in siblings and parents of pediatric probants. J. Pediatr., 1999, 135, 89.
22. Kural-Seyahi E., Fresko I., Sevahi N. et al.: The long-term mortality and morbidity of Behçet's syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore), 2003, 82, 60.
23. Lehner T., Lavery E., Smith R. et al.: Association between the 65-kilodalton heat shock protein, Streptococcus sanguis, and the corresponding antibodies in Behçet's syndrome. Infect. Immun., 1991, 59, 1434.
24. Lehner T., Losito A., Williams D.G.: Crioglobulins in Behçet's syndrome and recurrent oral ulceration assay by laser nephelometry. Clin. Exp. Immunol., 1979, 38, 436.
25. Mader R., Ziv M., Adawi M. et al.: Thrombophillic factors and their relation to thromboembolic and other clinical manifestations in Behçet's disease. J. Rheumatol., 1999, 26, 2404.
26. Meador R., Ehrlich G., Von Feldt J.M.: Behçet's disease: immunopathologic and therapeutic aspects. Curr. Rheumatol. Rep., 2002, 4, 47.
27. Miyamoto N., Mandai M., Suzuma I. et al.: Estrogen protects against cellular infiltration by reducing the expressions of E-selectin and IL-6 in endotoxin-induced uveitis. J. Immunol., 1999, 163, 374.
28. Mizuki N., Ota M., Katsuyama Y.: Sequencing-based typing of HLA-B*51 alleles and the significant association of HLA-B*5101 and -B*5108 with Behçet's disease in Greek patients. Tissue Antigens, 2002, 59, 118.
29. Mizushima Y.: Behçet's disease. Curr. Opin. Rheumatol., 1991, 3, 32.
30. Mizushima Y.: Recent research into Behçet's disease in Japan. Int. J. Tissue React., 1988, 10, 59.
31. Palacin V., Olalla J., Sanuy J.: Behçet's disease therapy review. Ann. Med. Interne, 2002, 19, 594.
32. Sedaroglu P., Yazici H., Ozdemir C. et al.: Neurologic involvement in Behçet's syndrome: A prospective study. Arch. Neurol., 1989, 46, 265.
33. Sfikakis P.P.: Behçet's disease: a new target for anti-tumor necrosis factor treatment. Ann. Rheum. Dis., 2002, 2, 151.
34. Shakir R.A., Sulaiman K., Kahn R.A., et al.: Neurological presentation of neuro-Behçet's syndrome: clinical categories. Eur. Neurol., 1990, 30, 249.
35. Stun U.C.: A famoust Turkish dermatologist, Dr. Hulusi Behçet. Eur. J. Dermatol., 2002, 12, 469.
36. Tanaka T., Yamakawa N., Koike N. et al.: Behçet's disease and antybody titers to various heat-shock protein 60s. Ocul. Immunol. Inflam., 1999, 7, 69.
37. Toio M., Zheng X., Yanagihori H.: Detection of herpes virus genomes in skin lesions from patients with Behçet's disease and other related inflammatory diseases. Acta. Derm. Venereol., 2003, 83, 124.
38. Tursen U., Gurler A., Boyvat A.: Evaluation of clinical findings according to sex in 2313 Turkish patients with Behçet's disease. Int. J. Dermatol., 2003, 42, 346.
39. Verity D.H., Wallace Gr., Vaughan R.W. et al.: HLA and tumor necrosis factor (TNF) polymorphism in ocular Behçet's disease. Tissue Antigens, 1999, 54, 264.
40. Wechsler B., Du L.T., Kieffer E.: Cardiovascular manifestations of Behçet's disease. Ann. Med. Internae, 1999, 150, 542.
41. Wechsler B., Sabi A., Du-Boutin L.T. et al.: Neurological manifestations of Behçet's disease. Rev. Neurol., 2002, 158, 926.
42. Yazici H., Barnes C.G.: Practical recommandations for pharmacotherapy of Behçets syndrome. Drugs, 1991, 42, 796.
43. Yazici H., Yurdakul S., Hamuryudan V.: Behçet disease. Curr. Opin. Rheumatol., 2001, 13, 18.
44. Yazici H., Yurdakul S., Hamuryudan V.: The management of Behçet's syndrome: how are we doing? Clin. Exp. Rheumatol., 1999, 17, 145.
45. Yoshikawa K., Kotake S., Matsuda H.: Behçet's disease and streptococcal antigens. Nippon Ganka Gakkai Zasshi, 1996, 100, 173.
46. Yurdakul S., Günaydin I., Tüzün Y et al.: The prevalence of Behçet's syndrome in a rural area in Northern Turkey. J. Rheumatol., 1988, 15, 820.
47. Yurdakul S., Mat C., Tüzün Y.: A double-blind trial of colchicine in Behçet's syndrome. Arthritis Rheum., 2001, 44, 2686.
48. Zouboulis C.C., Kotter I., Djawari D. et al.: Epidemiological features of Adamantiades Behçets disease in Germany and in Europe. Yonsei Med. J., 1997, 38, 411.
49. Zouboulis C.C.: Benediktos Adamantiades and his forgotten contributions to medicine. Eur. J. Dermatol., 2002, 12, 471.